Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

ALS Cognitive Behavioral Screen (ALS-CBS): normative values for the Italian population and clinical usability.

Tremolizzo L, Lizio A, Santangelo G, Diamanti S, Lunetta C, Gerardi F, Messina S, La Foresta S, Riva N, Falzone Y, Filippi M, Woolley SC, Sansone VA, Siciliano M, Ferrarese C, Appollonio I; ALS-CBS Italian Study Group.

Neurol Sci. 2019 Dec 5. doi: 10.1007/s10072-019-04154-1. [Epub ahead of print]

PMID:
31807998
2.

A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy.

Messina S, Frongia AL, Antonaci L, Pera MC, Coratti G, Pane M, Pasternak A, Civitello M, Montes J, Mayhew A, Finkel R, Muntoni F, Mercuri E; ISMAc group.

Neuromuscul Disord. 2019 Oct 22. pii: S0960-8966(19)31157-5. doi: 10.1016/j.nmd.2019.10.001. [Epub ahead of print] Review.

PMID:
31791871
3.

Longitudinal natural history in young boys with Duchenne muscular dystrophy.

Coratti G, Brogna C, Norcia G, Ricotti V, Abbott L, D'Amico A, Berardinelli A, Vita GL, Lucibello S, Messina S, Sansone V, Albamonte E, Colia G, Salmin F, Gardani A, Manzur A, Main M, Baranello G, Arnoldi MT, Parsons J, Carry T, Connolly AM, Bertini E, Muntoni F, Pane M, Mercuri E.

Neuromuscul Disord. 2019 Nov;29(11):857-862. doi: 10.1016/j.nmd.2019.09.010. Epub 2019 Sep 26.

PMID:
31629611
4.

Development of an academic disease registry for spinal muscular atrophy.

Mercuri E, Finkel R, Scoto M, Hall S, Eaton S, Rashid A, Balashkina J, Coratti G, Pera MC, Samsuddin S, Civitello M, Muntoni F; iSMAC Group.

Neuromuscul Disord. 2019 Oct;29(10):794-799. doi: 10.1016/j.nmd.2019.08.014. Epub 2019 Aug 29.

PMID:
31558335
5.

Long-term progression in type II spinal muscular atrophy: A retrospective observational study.

Mercuri E, Lucibello S, Pera MC, Carnicella S, Coratti G, de Sanctis R, Messina S, Mazzone E, Forcina N, Fanelli L, Norcia G, Antonaci L, Frongia AL, Pane M.

Neurology. 2019 Sep 24;93(13):e1241-e1247. doi: 10.1212/WNL.0000000000008166. Epub 2019 Aug 26.

PMID:
31451515
6.

Correction: Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.

Brogna C, Coratt G, Pane M, Ricotti V, Messina S, D'Amico A, Bruno C, Vita G, Berardinelli A, Mazzone E, Magri F, Ricci F, Mongini T, Battini R, Bello L, Pegoraro E, Baranello G, Previtali SC, Politano L, Comi GP, Sansone VA, Donati A, Bertini E, Muntoni F, Goemans N, Mercuri E; on behalf on the International DMD group.

PLoS One. 2019 Jul 31;14(7):e0220714. doi: 10.1371/journal.pone.0220714. eCollection 2019.

7.

Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53.

Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, Bruno C, Vita G, Berardinelli A, Mazzone E, Magri F, Ricci F, Mongini T, Battini R, Bello L, Pegoraro E, Baranello G, Previtali SC, Politano L, Comi GP, Sansone VA, Donati A, Bertini E, Muntoni F, Goemans N, Mercuri E; on behalf on the International DMD group.

PLoS One. 2019 Jun 25;14(6):e0218683. doi: 10.1371/journal.pone.0218683. eCollection 2019. Erratum in: PLoS One. 2019 Jul 31;14(7):e0220714.

8.

Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data.

Pane M, Coratti G, Sansone VA, Messina S, Bruno C, Catteruccia M, Sframeli M, Albamonte E, Pedemonte M, D'Amico A, Bravetti C, Berti B, Brigati G, Tacchetti P, Salmin F, de Sanctis R, Lucibello S, Piastra M, Genovese O, Bertini E, Vita G, Tiziano FD, Mercuri E; Italian Expanded Access Program Working Group.

Ann Neurol. 2019 Sep;86(3):443-451. doi: 10.1002/ana.25533. Epub 2019 Jul 8.

PMID:
31228281
9.

Comparative Analysis of C9orf72 and Sporadic Disease in a Large Multicenter ALS Population: The Effect of Male Sex on Survival of C9orf72 Positive Patients.

Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, Scialò C, Sorarù G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chiò A, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurrò MR, Tedeschi G, Mandrioli J.

Front Neurosci. 2019 May 17;13:485. doi: 10.3389/fnins.2019.00485. eCollection 2019.

10.

The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence.

Iolascon G, Vitacca M, Carraro E, Chisari C, Fiore P, Messina S, Mongini TEG, Sansone VA, Toscano A, Siciliano G.

Acta Myol. 2018 Dec 1;37(4):241-251. eCollection 2018 Dec. Review.

11.

Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.

Vita G, Vita GL, Musumeci O, Rodolico C, Messina S.

Neurol Sci. 2019 Apr;40(4):671-681. doi: 10.1007/s10072-019-03764-z. Epub 2019 Feb 25. Review.

PMID:
30805745
12.

Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis.

Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G; ITALSGEN Consortium; International ALS Genomics Consortium, Tienari PJ, Stone DJ, Nalls MA, Singleton AB, Chiò A, Traynor BJ.

Ann Neurol. 2019 Apr;85(4):470-481. doi: 10.1002/ana.25431. Epub 2019 Mar 13.

PMID:
30723964
13.

Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol.

Tiziano FD, Lomastro R, Abiusi E, Pasanisi MB, Di Pietro L, Fiori S, Baranello G, Angelini C, Sorarù G, Gaiani A, Mongini T, Vercelli L, Mercuri E, Vasco G, Pane M, Vita G, Vita G, Messina S, Petillo R, Passamano L, Politano L, Campanella A, Mantegazza R, Morandi L.

J Med Genet. 2019 May;56(5):293-300. doi: 10.1136/jmedgenet-2018-105482. Epub 2018 Dec 28.

PMID:
30593463
14.

Hippo signaling pathway is altered in Duchenne muscular dystrophy.

Vita GL, Polito F, Oteri R, Arrigo R, Ciranni AM, Musumeci O, Messina S, Rodolico C, Di Giorgio RM, Vita G, Aguennouz M.

PLoS One. 2018 Oct 10;13(10):e0205514. doi: 10.1371/journal.pone.0205514. eCollection 2018.

15.

Clinical management of Duchenne muscular dystrophy: the state of the art.

Messina S, Vita GL.

Neurol Sci. 2018 Nov;39(11):1837-1845. doi: 10.1007/s10072-018-3555-3. Epub 2018 Sep 14. Review.

PMID:
30218397
16.

New Directions for SMA Therapy.

Messina S.

J Clin Med. 2018 Aug 31;7(9). pii: E251. doi: 10.3390/jcm7090251. Review.

17.

The relationship between deficit in digit span and genotype in nonsense mutation Duchenne muscular dystrophy.

Thangarajh M, Elfring GL, Trifillis P, McIntosh J, Peltz SW; Ataluren Phase 2b Study Group.

Neurology. 2018 Sep 25;91(13):e1215-e1219. doi: 10.1212/WNL.0000000000006245. Epub 2018 Aug 22.

18.

An observational study of functional abilities in infants, children, and adults with type 1 SMA.

Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, Sframeli M, Albamonte E, Pedemonte M, D'Amico A, Brigati G, de Sanctis R, Coratti G, Lucibello S, Bertini E, Vita G, Danilo Tiziano F, Mercuri E; Italian EAP Working Group.

Neurology. 2018 Aug 21;91(8):e696-e703. doi: 10.1212/WNL.0000000000006050. Epub 2018 Jul 25.

19.

Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center.

La Foresta S, Faraone C, Sframeli M, Vita GL, Russo M, Profazio C, Rulli I, Gitto E, Versaci A, Messina S, Vita G.

Neurol Sci. 2018 Nov;39(11):1961-1964. doi: 10.1007/s10072-018-3506-z. Epub 2018 Jul 25.

PMID:
30043247
20.

Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function.

Pane M, Palermo C, Messina S, Sansone VA, Bruno C, Catteruccia M, Sframeli M, Albamonte E, Pedemonte M, D'Amico A, Brigati G, de Sanctis R, Coratti G, Lucibello S, Bertini E, Vita G, Tiziano FD, Mercuri E; Italian EAP working group.

Neuromuscul Disord. 2018 Jul;28(7):582-585. doi: 10.1016/j.nmd.2018.05.010. Epub 2018 Jun 1.

PMID:
29960818

Supplemental Content

Loading ...
Support Center